FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. KKR
7. P
8. NTNX
9. HPQ
10. A

Go back to FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
(NASDAQ: ARQT) Delayed: 24.82 -0.32 (1.27%)
Previous Close $25.14    52 Week High $ 
Open $24.95    52 Week Low $ 
Day High $25.15    P/E N/A 
Day Low $24.60    EPS $ 
Volume 288,720       

(NASDAQ: ARQT) Delayed: 24.82 -0.32 (1.27%)
Previous Close $25.14    52 Week High $ 
Open $24.95    52 Week Low $ 
Day High $25.15    P/E N/A 
Day Low $24.60    EPS $ 
Volume 288,720